Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Gulidanna Shayan(Tsinghua University), Robert L. Ferris(University of Pittsburgh), Robert M. Hershberg(Hebrew University of Jerusalem), Dwight E. Heron(Bon Secours Mercy Health), Sandra P. Gibson(UPMC Hillman Cancer Center), Umamaheswar Duvvuri(City University of New York), Benjamin Kansy(Essen University Hospital), James Ohr(University of Pittsburgh), Julie E. Bauman(George Washington University), Seungwon Kim(UPMC Hillman Cancer Center), Raghvendra M. Srivastava(University of Pittsburgh), Jonas T. Johnson(University of Pittsburgh), James Kyle Bryan, David A. Clump(West Virginia University)
Cited by 80
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590